| Drug Name: | Tranexamic Acid (1197-18-8) |
|---|---|
| PubChem ID: | 5526 |
| SMILES: | C1CC(CCC1CN)C(=O)O |
| InchiKey: | GYDJEQRTZSCIOI-UHFFFAOYSA-N |
| Therapeutic Category: | Antifibrinolytic Agents, Coagulants, Fibrin Modulating Agents, Hematologic Agents, Hemostatics |
| Molecular Weight (dalton) | : | 157.213 |
| LogP | : | 0.8361 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 63.32 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Tretinoin (302-79-4) | Kidney Cortex Necrosis | Additive | Tretinoin alone causes a procoagulant tendency in acute promyelocytic leukaemia (APL) and this may be exacerbated by use of antifibrinolytics. | All-Trans Retinoic Acid (Atra) and Tranexamic Acid: A Potentially Fatal Combination In Acute Promyelocytic Leukaemia |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category